JP2011521986A - 癌に対する４，６−ジフェニルピリド−２−オン - Google Patents

癌に対する４，６−ジフェニルピリド−２−オン Download PDF

Info

Publication number
JP2011521986A
JP2011521986A JP2011512021A JP2011512021A JP2011521986A JP 2011521986 A JP2011521986 A JP 2011521986A JP 2011512021 A JP2011512021 A JP 2011512021A JP 2011512021 A JP2011512021 A JP 2011512021A JP 2011521986 A JP2011521986 A JP 2011521986A
Authority
JP
Japan
Prior art keywords
lower alkyl
compound according
independently
halo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521986A5 (enExample
Inventor
ジェラード・アンドリュー・ポッター
フィリップ・ハクスリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incanthera Therapeutics Ltd
Original Assignee
Spear Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spear Therapeutics Ltd filed Critical Spear Therapeutics Ltd
Publication of JP2011521986A publication Critical patent/JP2011521986A/ja
Publication of JP2011521986A5 publication Critical patent/JP2011521986A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011512021A 2008-06-04 2009-06-04 癌に対する４，６−ジフェニルピリド−２−オン Pending JP2011521986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0810228.7 2008-06-04
GBGB0810228.7A GB0810228D0 (en) 2008-06-04 2008-06-04 Novel compounds
PCT/EP2009/004005 WO2009146910A1 (en) 2008-06-04 2009-06-04 4, 6-diphenylpyrid-2-0nes against cancer

Publications (2)

Publication Number Publication Date
JP2011521986A true JP2011521986A (ja) 2011-07-28
JP2011521986A5 JP2011521986A5 (enExample) 2014-06-26

Family

ID=39638174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512021A Pending JP2011521986A (ja) 2008-06-04 2009-06-04 癌に対する４，６−ジフェニルピリド−２−オン

Country Status (7)

Country Link
US (2) US8236827B2 (enExample)
EP (1) EP2310370A1 (enExample)
JP (1) JP2011521986A (enExample)
AU (1) AU2009254176A1 (enExample)
CA (1) CA2726939A1 (enExample)
GB (1) GB0810228D0 (enExample)
WO (1) WO2009146910A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524738A (ja) * 2016-07-13 2019-09-05 セントレ ナシオナル デ ラ ルシェルシェ シエンティフィーク ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058550A2 (en) * 2010-10-29 2012-05-03 Fox Chase Cancer Center Methods for screening compounds for capability to inhibit premalignant squamous epithelial cell progression to a malignant state
US9101603B2 (en) 2010-11-30 2015-08-11 Institute For Cancer Research Targeting of CYP1B1 in the treatment of head and neck cancer and lung cancer
CN103387574A (zh) * 2012-05-07 2013-11-13 北京以岭药业有限公司 一种表小檗碱的合成方法
CN107591180A (zh) * 2016-07-07 2018-01-16 中芯国际集成电路制造(上海)有限公司 非挥发性存储器及其读取数据的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072833A1 (en) * 2005-09-29 2007-03-29 Wendt Michael D Survivin inhibitors
JP2010525062A (ja) * 2007-04-25 2010-07-22 エグゼリクシス， インコーポレイテッド Ｐｉｍモジュレーターとしてのピリミジノン類

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072833A1 (en) * 2005-09-29 2007-03-29 Wendt Michael D Survivin inhibitors
JP2010525062A (ja) * 2007-04-25 2010-07-22 エグゼリクシス， インコーポレイテッド Ｐｉｍモジュレーターとしてのピリミジノン類

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN7013004000; Ｍａｒｉａ　Ｈ．　Ｐａｌｕｃｈｏｗｓｋａ　ｅｔ　ａｌ．: Ｐｏｌｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．５３, 2001, ｐ．３６９-３７６ *
JPN7013004001; Ｐｈｉｌｉｐｐ　Ｇｒｏｓｃｈｅ　ｅｔ　ａｌ．: Ｓｙｎｔｈｅｓｉｓ Ｎｏ．１１, 1999, ｐ．１９６１-１９７０ *
JPN7013004002; Ａｌａｎ　Ｒ．　Ｋａｔｒｉｔｚｋｙ　ｅｔ　ａｌ．: Ｊｏｕｒｎａｌ　ｏｆ　Ｃｏｍｂｉｎａｔｏｒｉａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４，　Ｎｏ．４, 2002, ｐ．２４９-２５０ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524738A (ja) * 2016-07-13 2019-09-05 セントレ ナシオナル デ ラ ルシェルシェ シエンティフィーク ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
JP7092742B2 (ja) 2016-07-13 2022-06-28 セントレ ナシオナル デ ラ ルシェルシェ シエンティフィーク ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用

Also Published As

Publication number Publication date
US20130023567A1 (en) 2013-01-24
GB0810228D0 (en) 2008-07-09
CA2726939A1 (en) 2009-12-10
US20100168180A1 (en) 2010-07-01
US8236827B2 (en) 2012-08-07
AU2009254176A1 (en) 2009-12-10
WO2009146910A8 (en) 2011-04-07
EP2310370A1 (en) 2011-04-20
WO2009146910A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
US20250295789A1 (en) Treatment or prophylaxis of proliferative conditions
US20210380626A1 (en) Novel small molecule drug conjugates of gemcitabine derivatives
US8236827B2 (en) Compounds
US10793509B2 (en) Compounds useful in the treatment of neoplastic diseases
AU2013203591B2 (en) Treatment or prophylaxis of proliferative conditions
JP2011016754A (ja) 置換フェナントレン化合物を有効成分とするがんを予防および／または治療するための医薬組成物
WO2012164969A1 (ja) 置換フェナントレン化合物を有効成分とするがんを予防および／または治療するための医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140305

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140409

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630